Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Molecular Phenotyping in IBD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* inflammatory bowel disease~* indication for biological therapy~Exclusion Criteria:~* pregnancy, breast feeding~* no written informed consent to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: ACTIVE_COMPARATOR): 5 mg/kg body weight, week 0/2/6, then every 8 weeks
- Vedolizumab (Type: ACTIVE_COMPARATOR): 300 mg, week 0/2/6, then every 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).